Jump to navigation Jump to search
Clinical data
  • AU: X (High risk)
Routes of
Oral, IM
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
Pharmacokinetic data
Protein binding71%
MetabolismHepatic (CYP3A4, CYP1A2, CYP2D6)
Elimination half-life6–8 hours
ExcretionRenal, Fecal
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass284.353 g/mol
3D model (JSmol)

WikiDoc Resources for Tropisetron


Most recent articles on Tropisetron

Most cited articles on Tropisetron

Review articles on Tropisetron

Articles on Tropisetron in N Eng J Med, Lancet, BMJ


Powerpoint slides on Tropisetron

Images of Tropisetron

Photos of Tropisetron

Podcasts & MP3s on Tropisetron

Videos on Tropisetron

Evidence Based Medicine

Cochrane Collaboration on Tropisetron

Bandolier on Tropisetron

TRIP on Tropisetron

Clinical Trials

Ongoing Trials on Tropisetron at Clinical

Trial results on Tropisetron

Clinical Trials on Tropisetron at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tropisetron

NICE Guidance on Tropisetron


FDA on Tropisetron

CDC on Tropisetron


Books on Tropisetron


Tropisetron in the news

Be alerted to news on Tropisetron

News trends on Tropisetron


Blogs on Tropisetron


Definitions of Tropisetron

Patient Resources / Community

Patient resources on Tropisetron

Discussion groups on Tropisetron

Patient Handouts on Tropisetron

Directions to Hospitals Treating Tropisetron

Risk calculators and risk factors for Tropisetron

Healthcare Provider Resources

Symptoms of Tropisetron

Causes & Risk Factors for Tropisetron

Diagnostic studies for Tropisetron

Treatment of Tropisetron

Continuing Medical Education (CME)

CME Programs on Tropisetron


Tropisetron en Espanol

Tropisetron en Francais


Tropisetron in the Marketplace

Patents on Tropisetron

Experimental / Informatics

List of terms related to Tropisetron

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Tropisetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy, although it has been used experimentally as an analgesic in cases of fibromyalgia.[1] The drug is available in a 5 mg oral preparation or in 2 mg intravenous form. It is marketed by Novartis in Europe, Australia and New Zealand as Navoban, but is not available in the U.S.

Adverse effects

Tropisetron is a well-tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drug's use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.

External links


  1. Muller, W. (2004). "Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron". Scand J Rheumatic Suppl. 119: 44–48. PMID 15515413. Retrieved 2007-05-17. Unknown parameter |coauthors= ignored (help)

Template:5-HT3 antagonists